Table 2.
Logistic regression analyses for in-hospital mortality.
| Variable | Univariate OR (95% CI) | Univariate p | Adjusted OR without count (95% CI) | Adjusted p without count | Monitoring-adjusted OR (95% CI) | Monitoring-adjusted p |
|---|---|---|---|---|---|---|
| Platelet count CV, per 0.1 | 1.28 (1.17–1.40) | <0.001 | 0.99 (0.88–1.11) | 0.901 | 1.21 (1.07–1.38) | 0.003 |
| Platelet measurement count, per measurement | 0.97 (0.95–1.00) | 0.061 | — | — | 0.84 (0.81–0.88) | <0.001 |
| Age, per year | 1.01 (1.00–1.02) | 0.014 | 1.02 (1.01–1.04) | <0.001 | 1.02 (1.01–1.03) | <0.001 |
| Male (vs female) | 1.06 (0.83–1.35) | 0.664 | 0.96 (0.73–1.26) | 0.761 | 0.97 (0.73–1.28) | 0.823 |
| GCS, per point | 0.95 (0.91–0.99) | 0.009 | 1.05 (1.00–1.10) | 0.054 | 1.04 (0.99–1.10) | 0.096 |
| SOFA, per point | 1.26 (1.21–1.32) | <0.001 | 1.21 (1.13–1.29) | <0.001 | 1.19 (1.12–1.27) | <0.001 |
| Baseline platelet count, per 10 K/μL | 0.97 (0.95–0.98) | <0.001 | 0.99 (0.97–1.01) | 0.395 | 1.00 (0.98–1.02) | 0.851 |
| AKI (yes vs. no) | 2.92 (2.24–3.80) | <0.001 | 1.74 (1.24–2.42) | 0.001 | 2.19 (1.54–3.11) | <0.001 |
| Pneumonia (yes vs. no) | 2.31 (1.78–3.00) | <0.001 | 1.50 (1.11–2.01) | 0.008 | 2.15 (1.56–2.97) | <0.001 |
| CKD (yes vs. no) | 1.52 (1.09–2.12) | 0.014 | 0.98 (0.66–1.46) | 0.918 | 0.99 (0.65–1.49) | 0.945 |
| Myocardial infarction (yes vs. no) | 2.72 (1.68–4.40) | <0.001 | 1.73 (1.00–3.02) | 0.051 | 1.97 (1.10–3.52) | 0.023 |
| Anticoagulant use (yes vs. no) | 0.57 (0.34–0.97) | 0.037 | 0.39 (0.22–0.71) | 0.002 | 0.52 (0.28–0.97) | 0.040 |
| Surgery (yes vs. no) | 2.03 (1.42–2.92) | <0.001 | 2.67 (1.76–4.05) | <0.001 | 3.39 (2.20–5.23) | <0.001 |
| CRRT (yes vs. no) | 8.32 (4.65–14.88) | <0.001 | 2.56 (1.23–5.31) | 0.012 | 2.76 (1.29–5.92) | 0.009 |
| Mechanical ventilation (yes vs. no) | 2.54 (1.83–3.53) | <0.001 | 1.49 (1.03–2.14) | 0.032 | 1.95 (1.34–2.84) | <0.001 |
| Platelet transfusion (yes vs. no) | 2.68 (1.76–4.08) | <0.001 | 1.19 (0.70–2.02) | 0.524 | 1.22 (0.70–2.12) | 0.490 |
| ICH location: Cerebral lobe (vs deep hemorrhage) | 0.78 (0.55–1.10) | 0.160 | 0.79 (0.42–1.48) | 0.465 | 0.73 (0.38–1.38) | 0.333 |
| ICH location: Brainstem (vs deep hemorrhage) | 2.28 (1.14–4.57) | 0.020 | 3.52 (1.40–8.84) | 0.008 | 3.27 (1.27–8.43) | 0.014 |
| ICH location: Cerebellum (vs deep hemorrhage) | 0.94 (0.53–1.68) | 0.843 | 0.90 (0.41–1.99) | 0.790 | 0.88 (0.38–2.02) | 0.763 |
| ICH location: Ventricle (vs deep hemorrhage) | 1.63 (1.16–2.29) | 0.004 | 1.69 (0.91–3.13) | 0.096 | 1.83 (0.96–3.47) | 0.065 |
| ICH location: Multifocal hemorrhage (vs deep hemorrhage) | 1.53 (0.51–4.59) | 0.444 | 1.73 (0.49–6.14) | 0.395 | 1.86 (0.51–6.76) | 0.349 |
| ICH location: Others (vs deep hemorrhage) | 0.89 (0.70–1.14) | 0.354 | 1.10 (0.63–1.93) | 0.727 | 1.00 (0.56–1.77) | 0.997 |
| Race: Black (vs White) | 0.86 (0.56–1.32) | 0.481 | 1.17 (0.72–1.91) | 0.519 | 1.30 (0.80–2.13) | 0.294 |
| Race: Asian (vs White) | 0.90 (0.47–1.71) | 0.748 | 1.61 (0.81–3.23) | 0.176 | 1.81 (0.89–3.68) | 0.099 |
| Race: Others (vs White) | 2.43 (1.88–3.13) | <0.001 | 2.45 (1.82–3.30) | <0.001 | 2.67 (1.96–3.63) | <0.001 |
Platelet count CV is reported per 0.1-unit increase. The monitoring-adjusted model additionally included platelet measurement count. N = 2,202; events = 294. GCS, Glasgow Coma Scale; SOFA, Sequential Organ Failure Assessment:; APSIII, Acute Physiology Score III; SAPSII, Simplified Acute Physiology Score II; HR, Heart Rate; RR, Respiratory Rate; NBPS, Non-invasive Blood Pressure Systolic; NBPD, Non-invasive Blood Pressure Diastolic; RDW, Red Cell Distribution Width; RBC, Red Blood Cell; WBC, White Blood Cell; AG, Anion Gap; PT, Prothrombin Time; PTT, Partial Thromboplastin Time; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; TBIL, Total Bilirubin; SLE, Systemic Lupus Erythematosus; ALL, Acute Lymphoblastic Leukemia; MDS, Myelodysplastic Syndrome; ITP, Immune Thrombocytopenic Purpura; TP, Thrombocytopenia; AKI, Acute Kidney Injury; HTN, Hypertension; LC, Liver Cirrhosis; HEP, Hepatitis; PNA, Pneumonia; CKD, Chronic Kidney Disease; CA, Carcinoma; T2DM, Type 2 Diabetes Mellitus; HLD, Hyperlipidemia; HF, Heart Failure; MI, Myocardial Infarction; COPD, Chronic Obstructive Pulmonary Disease; Anti-coa, Anticoagulation agent; Anti-pla, Antiplatelet agent; CRRT, Continuous Renal Replacement Therapy; Platelet count CV, Coefficient of Variation of Platelet Count.